Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Capital Expenditures (2016 - 2025)

Macrogenics (MGNX) has disclosed Capital Expenditures for 14 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 1807.0% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 1814.0% increase, with the full-year FY2025 number at $1.9 million, up 1814.0% from a year prior.
  • Capital Expenditures was $1.9 million for Q4 2025 at Macrogenics, up from -$1.2 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $6.1 million in Q4 2021 to a low of -$2.5 million in Q3 2024.
  • A 5-year average of $680100.0 and a median of $355000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: crashed 4248.98% in 2022, then skyrocketed 1807.0% in 2025.
  • Macrogenics' Capital Expenditures stood at $6.1 million in 2021, then tumbled by 45.73% to $3.3 million in 2022, then tumbled by 51.98% to $1.6 million in 2023, then crashed by 93.74% to $100000.0 in 2024, then surged by 1807.0% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Capital Expenditures are $1.9 million (Q4 2025), -$1.2 million (Q3 2025), and $715000.0 (Q2 2025).